Assessment of griseofulvin in the management of lichen planus
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20175376Keywords:
Griseofulvin, Lichen planus, Pathologically, TreatmentAbstract
Background: Oral lichen planus (OLP) is a common mucocutaneous disorder that affects 1-2% of the adult general population and slight predominance in females has been observed. The success rate is not satisfactory with these modalities of treatment, so there is a clear need for alternative therapy. This study was done to evaluate the efficacy of griseofulvin in the treatment of lichen planus.
Methods: The present study was conducted in the department of dermatology in the medical institution for the period of one year. The study included the initial assessment of 60 patients who were diagnosed with lichen planus (LP). Patients with both sexes and age between 15-60 years who agreed to come on follow up examination were included. All patients were treated with griseofulvin 500 mg/day for 6 months. Response of treatment was assessed by clinical examination at each subsequent visit (every two weeks).
Results: Among patients with OLP, there was complete response in 27%, moderate improvement in 51%, and no response in 22% of cases. Complete clinical response of cutaneous LP was seen in 18% cases, no response was found in same number of patient, 64% no. of cases showed moderate response.
Conclusions: Griseofulvin gives complete improvement in 27% cases and moderate improvement in 51% cases in OLP and it gives complete improvement in 16% cases in cutaneous LP after treatment of 6 months. This study was done on a small scale and without any control group, so conclusive comments could not be passed.
Metrics
References
Kumar S, Kumar V, Kumar P. Lichen Planus: A Case with Mucocutaneous and Genital Involvement.
Nisengard RJ, Neiders M. Desquamative lesions of the gingiva. J periodontal. 1981;52:500-10.
Moravvej H, Hoseini H, Barikbin B, Malekzadeh R, Razavi GM. Association of Helicobacter pylori with lichen planus. Indian J Dermatol. 2007;52:138.
Carrozzo M, Brancatello F, Dametto E, Arduino P, Pentenero M, Rendine S, et al. Hepatitis C virus‐associated oral lichen planus: is the geographical heterogeneity related to HLA‐DR6? J Oral Pathol Med. 2005;34:204-8.
Keshari D, Karthikeya Patil MV. Efficacy of topical curcumin in the management of oral lichen planus: A randomized controlled-trial. J Adv Clin Res Insights. 2015;2:197-203.
Robledo-Sierra J. Oral Lichen Planus-a study of associated factors with special reference to thyroid disease, 2015.
Piguet V, Breathnach SM, Le Cleach L. Lichen planus and lichenoid disorders. Rook's Textbook of Dermatology. 2016.
Arun T. The clinical and pathological study of autoimmune vesiculobullous disorders. 2011.
Krupaa RJ, Sankari SL, Masthan K, Rajesh E. Oral lichen planus: An overview. J Pharmacy Bioallied Sci. 2015;7:158.
Muthuswamy M, Prabuseenivasan, Kumar V. Screening Of Antitubercular Activity Of Some Medicinal Plants From Western Ghats, India. Int J Pharm Bio Sci. 2013;4(4):328-34.
Jayachandran S, Koijam Sashikumar S: Management of oral lichen plannus: A clinical study. Management. 2012;25:205.
Bhuiyan I, Wahab M, Ali A, Sultana A, Siddique RU, Hawlader AR, et al. Comparative efficacy of hydroxychloroquine and griseofulvin in the treatment of lichen planus. J Pakistan Assoc Dermatol. 2016;20:79-83.
Bagan J, Silvestre F, Mestre S, Gisbert C, Bermejo A, Agramunt J. Treatment of lichen planus with griseofulvin: report of seven cases. Oral Surg Oral Med Oral Pathol. 1985;60:608-10.
Massa M, Rogers 3rd R. Griseofulvin therapy of lichen planus. Acta dermato-venereologica 1981;61:547-50.
Cribier B, Frances C, Chosidow O. Treatment of lichen planus: an evidence-based medicine analysis of efficacy. Archives of Dermatol. 1998;134:1521-30.
Sehgal V, Abraham G, Malik GB. Griseofulvin therapy in lichen planus. Br J Dermatol. 1972;87:383-5.
Downloads
Published
How to Cite
Issue
Section
